title: [Application of (125)I seeds combined with biliary stent implantation in the treatment of malignant obstructive jaundice].
abstract: OBJECTIVE
  To study the feasibility and therapeutic effect of the application of (125)I seeds combined with biliary stent implantation on the treatment of malignant obstructive jaundice.
  
  
  METHODS
  Fifty patients with malignant obstructive jaundice treated from September 2010 to February 2013 in Yantai Yuhuangding Hospital were included in this study. Among them, 24 patients received biliary stent implantation combined with (125)I seeds intraluminal brachytherapy as experimental group, and 26 were treated by biliary stent implantation as control group.The total bilirubin, direct bilirubin and tumor markers (CA-199, CA-242, CEA) before and after surgery, the biliary stent patency status was assessed, and the survival time was evaluated.
  
  
  RESULTS
  The 24 patients in experimental group were implanted with 30 (125)I seeds successfully in a total of 450 seeds. Jaundice was improved greatly in both groups. The CA-199 and CA-242 after treatment in the experimental group were significantly decreased than that before treatment (P=0.003 and P=0.004). CEA was also decreased, but showed no statistical significance (P>0.05). There were no significant improvement comparing the CA-199, CA-242 and CEA before and 2 months after surgery in the control group (P>0.05). The rate of biliary stent patency was 83.3% (20/24) in the experimental group and 57.7% (15/26) in the control group (P=0.048). The mean biliary stent patency time in the experimental group was 9.84 months (range 1-15.5 months). The mean biliary stent patency time in the control group was 5.57 months (range 0.8-9 months). There was a significant difference between the two groups (P=0.018). The median survival time was 10.2 months in the experimental group and 5.4 months in the control group (P<0.05).
  
  
  CONCLUSIONS
  (125)I seeds combined with biliary stent implantation can inhibit the proliferation of vascular endothelial cells and the growth of tumor effectively, and can prolong the biliary stent patency time and the survival time obviously for patients with malignant obstructive jaundice, therefore, is a safe and effective treatment in this malignancy.
authors.affiliation: Department of Interventional Therapy, Yuhuangding Hospital, Yantai 264000, China.
authors.forename: T
authors.initials: T
authors.lastname: Wang
authors.forename: S
authors.initials: S
authors.lastname: Liu
authors.forename: Y B
authors.initials: YB
authors.lastname: Zheng
authors.forename: X P
authors.initials: XP
authors.lastname: Song
authors.forename: W J
authors.initials: WJ
authors.lastname: Jiang
authors.forename: B L
authors.initials: BL
authors.lastname: Sun
authors.forename: L G
authors.initials: LG
authors.lastname: Wang
mesh_terms: D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001918:Brachytherapy / Q000379:methods*; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000032:analysis; D016022:Case-Control Studies; D003131:Combined Modality Therapy / Q000379:methods; D005240:Feasibility Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D041781:Jaundice, Obstructive / Q000097:blood / Q000401:mortality / Q000628:therapy*; D015607:Stents; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; C074601:CA 242 antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D007457:Iodine Radioisotopes; D001663:Bilirubin